Danielle Greenawalt

Danielle Greenawalt is an accomplished professional in the field of translational informatics and predictive sciences, currently serving as Vice President at Bristol Myers Squibb since May 2016, following a progression of leadership roles within the company. Prior to this, Danielle held key positions at AstraZeneca and Merck, focusing on oncology informatics, pharmacogenetics, and biomarker identification. Danielle began a research career as a postdoctoral fellow at Rosetta Inpharmatics and Peter MacCallum Cancer Centre, concentrating on genetic data analysis and gene expression related to cancer treatment responses. Holding a PhD in Molecular Genetics from Rutgers University and a BS in Molecular Biology from Lehigh University, Danielle has developed a robust expertise in applying bioinformatics to drive advancements in oncology and immuno-oncology.